Ascendis Pharma (ASND) Stock Statistics & Valuation Metrics

Ascendis Pharma has a market cap or net worth of $12.86B. The enterprise value is $12.40B.

Ascendis Pharma has 61,151,463 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascendis Pharma’s return on equity (ROE) is 3.58 and return on invested capital (ROIC) is -37.00%.

The current PE Ratio of Ascendis Pharma is ―. Ascendis Pharma’s PEG ratio is 0.86.

In the last 12 months, Ascendis Pharma had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.

In the last 12 months, operating cash flow was -106.68M and capital expenditures -5.48M, giving a free cash flow of -112.15M billion.

Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ascendis Pharma upcoming earnings date is Feb 12, 2026, TBA (Confirmed).

Ascendis Pharma as a current ratio of 1.17, with Debt / Equity ratio of -422.52%

In the past 12 months, Ascendis Pharma has paid 4.84M in taxes.

Ascendis Pharma EV to EBITDA ratio is -27.56, with an EV/FCF ratio of -25.99.

Ascendis Pharma has $539.09M in cash and marketable securities with $813.65M in debt, giving a net cash position of -$274.56M billion.

Gross margin is 84.88%, with operating margin of -76.66%, and net profit margin of -103.97%.

The average price target for Ascendis Pharma is $260.15, which is 11.43% higher than the current price. The consensus rating is Strong Buy